Locations:
Search IconSearch

Tag: multiple sclerosis (MS)

19-NEU-6534-Cohen-stem-cells-for-MS_Hero_650x450
January 17, 2020/Cancer

New BEAT-MS Trial Stages Direct Comparison of Stem Cells and Biologics for Relapsing MS

Knocking out, then restoring, the immune system holds great promise

Bethoux, MD

Adopting New Technologies for Multiple Sclerosis Rehabilitation (Podcast)

A veteran clinician shares insights on the care-enhancing qualities of tech

19-NEU-3979-relapsing-multiple-sclerosis-650×450
September 24, 2019/Neurosciences/Research

Phase 3 Ozanimod Trials Show Good Efficacy and Tolerability at 2 Years for Relapsing MS

Findings hint at potentially easier treatment initiation vs. other S1P receptor modulators

19-NEU-3855-Exoskeleton-650×450
July 31, 2019/Neurosciences/Research

Piloting a Powered Exoskeleton for Gait Training in Multiple Sclerosis

New study aims to assess a potential new indication for the technology

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

19-NEU-319-Caren-Treadmill-MS-650×450
June 4, 2019/Neurosciences/Research

Virtual Reality Platform’s Dynamic Approach to Physical Therapy Yields Benefits in MS

Preliminary study finds improved gait and balance vs. traditional PT

19-NEU-325-deep-gray-matter_650x450

Assessing Deep Gray Matter Atrophy as a Predictor of Clinical Disability in MS

Study finds strong association between brain/thalamic volume and T2 lesion volume

19-NEU-324-SPRINT-MS-650×450

SPRINT-MS Subanalysis Shows Greater Effect for Ibudilast in Primary Vs. Secondary Progressive MS

Findings may be due to faster atrophy progression in primary progressive MS

19-NEU-258-Woman-MS-Wheelchair-640241694
March 27, 2019/Neurosciences/Research

A Window into Patients’ Perceptions of the Risks of Multiple Sclerosis Therapies

Large survey shows wide variability in risk tolerance, high levels of risk aversion

18-NEU-5687-myelocortical-multiple-sclerosis-650×450

Myelocortical Multiple Sclerosis: Neurodegeneration Without White Matter Demyelination

Discovery of new MS subtype suggests that the axon itself may be primary site of injury

18-NEU-5744-MS-Therapy-650×450
November 12, 2018/Neurosciences/Research

Disease-Modifying Therapy for MS: Discontinuing After Age 60 Appears Safe

Observational study suggests age may be a better guide than disease stability

BackPage 7 of 8Next

Advertisement

Ad